News
Viking Therapeutics (VKTX 1.70%) is developing VK2735, a dual GLP-1/GIP receptor agonist for obesity treatment. The company ...
The Semaglutide peptide has emerged as a compelling subject in biochemical and physiological research due to its potential ...
For people who constantly think about what they are going to eat meal to meal, their food noise goes down significantly’ ...
Medications known as GLP-1 inhibitors have made headlines in recent years due to their effectiveness in managing blood sugar ...
Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...
A nutrition expert has shared a list of six types of foods that could help you to feel full for longer - and they may even ...
In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management ...
Lizzo has been on what she called an intentional weight release journey, and she's sharing more secrets behind her body transformation.
Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...
The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.
VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results